Mild Metabolic Hyperoxaluria. A New Syndrome

  • G. A. Rose
Part of the The Bloomsbury Series in Clinical Science book series (BLOOMSBURY)


The term “mild metabolic hyperoxaluria” (MMH) is being used to define a group of patients with the following characteristics:
  1. 1.

    The patients all have hyperoxaluria compared to healthy individuals of the same age and sex. Usually the urinary oxalate is only slightly elevated although in one or two cases very high levels have been seen

  2. 2.

    The word “metabolic” signifies that urinary glycollate is also elevated, approximately matching the urinary excretion of oxalate. This raised urinary glycollate proves that the hyperoxaluria is not due to over-ingestion or over-absorption of dietary oxalate (Rose and Kasidas 1979)

  3. 3.

    The clinical course is of severe and recurrent urolithiasis with stones made of pure calcium oxalate

  4. 4.

    In some cases it has been possible to measure oxalate in plasma and urine samples taken simultaneously and to show that both levels are raised. Hence the hyperoxaluria is due to raised plasma level and not to primary renal loss of oxalate. Plasma glycollate has not been measured, but it seems likely that it too is raised

  5. 5.

    Some patients respond dramatically to only 10 mg per day of pyridoxine. Others require higher doses and yet others will not respond even to 800 mg per day. This and other factors are described below



Primary Hyperparathyroidism Parathyroid Adenoma Calcium Oxalate Renal Tubular Acidosis Urinary Oxalate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Balcke P, Schmidt P, Zazgornik J, Kopsa H, Minar E (1983) Pyridoxine therapy in patients with renal calcium oxalate calculi. Proc Eur Dial Transplant Assoc Eur Ren Assoc 20: 417–421Google Scholar
  2. Barber GW, Spaeth GL (1967) Pyridoxine therapy in homocystinuria. Lancet I: 337CrossRefGoogle Scholar
  3. Frimpter GW, Haymovitz A, Horwith M (1963) Cystathioninuria. N Engl J Med 268: 333–339PubMedCrossRefGoogle Scholar
  4. Gibbs DA, Watts RWE (1970) The action of pyridoxine in primary hyperoxaluria. Clin Sci 38: 277–286PubMedGoogle Scholar
  5. Gill HS, Rose GA (1986) Mild metabolic hyperoxaluria and its response to pyridoxine. Urol Int 41: 393–396PubMedCrossRefGoogle Scholar
  6. Harrison AR, Kasidas GP, Rose GA (1981) Hyperoxaluria and recurrent stone formation apparently cured by short courses of pyridoxine. Br Med J 282: 2097–2098CrossRefGoogle Scholar
  7. Horrigan DL, Harris JW (1964) Pyridoxine responsive anaemia. Adv Intern Med 121: 163–174Google Scholar
  8. Hosking DH, Erickson SB, Van Den Berg CJ (1983) The stone chnic effect in patients with idiopathic calcium urolithiasis. J Urol 130: 1115–1118PubMedGoogle Scholar
  9. Hunt AD, Stokes SJ, McCrory WW, Stroud HH (1954) Pyridoxine dependency: a report of a case of intractable convulsions in an infant. Paediatrics 13: 140–145Google Scholar
  10. Jaeger H, Portmann L, Jacquet A-F, Burckhardt P (1986) La pyridoxine peut normaliser I’oxalurie dans la lithiasè rénale idiopathique. Schweiz Med Wochenschr 116: 1783–1786PubMedGoogle Scholar
  11. Kasidas GP, Rose GA (1984) Metabolie hyperoxaluria and its response to pyridoxine. In: Ryall R, Brockis JG, Marshall V, Finlayson B (eds) Urinary stone. Churchill-Livingstone, Melbourne, pp 138–147Google Scholar
  12. Murthy MSR, Farooqui S, Talwar HS, Thind SK, Nath R, Rajendran L, Bapna BC (1982) Effect of pyridoxine supplementation on recurrent stone formers. Int J Clin Pharm Therap Toxicol 20: 434–437Google Scholar
  13. Rose GA (1988a) Primary hyperparathyroidism. In: Wickham JEAW, Buck AC (eds) Renal tract stone: metabohc basis and chnical practice. Churchill-Livingstone, London, In pressGoogle Scholar
  14. Rose GA (1988b) The role of pyridoxine in stone prevention of hyperoxaluric patients. Urology Annual (In press)Google Scholar
  15. Rose GA, Kasidas GP (1979) New enzymatic method for measurement of plasma and urinary glycollate and its diagnostic value. In: Gasser G, Vahlensieck W (eds) Pathogenese und Klinik der Harnsteine VII. Steinkopf-Verlag, Darmstadt, pp 252–260CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • G. A. Rose

There are no affiliations available

Personalised recommendations